https://www.selleckchem.com/pr....oducts/Temsirolimus.
The 3-year overall survival (OS) was 97.2, 95.2, 68.3, and 71.8%; 3-year disease-free survival (DFS) was 94.5, 91.4, 60.2, and 59.2%, respectively, for patients with pN- and IL, pN- and SLNB, pN+ and IL, and pN+ and SLNB. Neither OS nor DFS showed significant difference between SLNB and IL in pN- (P = 0.564 for OS, P = 0.423 for DFS), or pN + patients (P = 0.920 for OS, P = 0.862 for DFS). With appropriate adjuvant radiotherapy, SLNB alone provided similar long-term survival compared with IL for both patients with and without senti
Beğen
Yorum Yap
Paylaş
